Our objective was to identify commercially available digoxin immunoassays whose cross-reactivity with digoxin metabolites paralleled the pharmacological activity of the metabolites. We measured the immunoreactivity of digoxigenin bis-and monodigitoxosides, digoxigenin, and dihydrodigoxin in four immunoassays and compared the immunoactivities with pharmacological activities from studies involving whole-animal and receptor (Na,KATPase)-based assays. Correlation coefficients for comparisons of immunoassay reactivity and human heart receptor reactivities were: ACS, 0. The pharmacological action of digoxin (and other digitalis-related cardiac glycosides) is mediated by interaction with its receptor, the sodium pump (Na,KATPase; EC 3.6.1.37). Investigators have used receptorbinding assays (8, 9) and other receptor-based functional assays (10-12) to measure pharmacologically active digoxin and other cardiac glycosides in serum. Digoxin undergoes metabolism to various deglycated, reduced, and polar metabolites (13-17), the extent and magnitude of which varies greatly between individuals taking the drug (13,14,16) .
immunoassays.
Immunoassays are capable of great analytical specificity;
however, the relative responses of drug metabolites (cross-reactivities) are often greater than (or less than) the pharmacological activity of the metabolites.
An immunochemical approach to solving this problem is to develop immunoassays for which the response would closely mimic a true measure of bioactivity.
This concept requires developing antibodies with binding properties (e.g., affinities, kinetics) towards bioactive ligands (parent compound and active metabolites) proportional to the relative response of those ligands to their natural receptors.
In selecting such antibodies, one must demonstrate equivalence of response in the immunoassay and biological assays to the individual metabolic components of the drug.
Digoxin
can serve as a model to demonstrate these concepts.
The pharmacological action of digoxin (and other digitalis-related cardiac glycosides) is mediated by interaction with its receptor, the sodium pump (Na,KATPase; EC 3.6.1.37). Investigators have used receptorbinding assays (8, 9) and other receptor-based functional assays (10-12) to measure pharmacologically active digoxin and other cardiac glycosides in serum. Digoxin undergoes metabolism to various deglycated, reduced, and polar metabolites (13-17), the extent and magnitude of which varies greatly between individuals taking the drug (13,14,16).
The pharmacological activities of some of these metabolites have been measured by using both animal models (18) (19) (20) (21) and receptor-binding techniques (9, 22 ability to measure digoxin and its metabolites in a manner reflective of the relative bioactivities of these analytes. 
Materials and Methods

Materials
Immunoreactivity of combined mixtures of digoxin me-
tabolites. Because patients' sera contain a mixture of digoxin with its metabolites, we prepared a series of mixtures of Dig, DB, DM, and DG. DHD was not included because it reportedly has insignificant bioactivity and because it had insignificant cross-reactivity in all immunoassays we tested. These mixtures were assayed in the ACS, TDx, Stratus, and Magic digoxin assays. These results are listed in Table 3 and graphed in Fig. 3 .
Discussion
In this study we used digoxin immunoassays as a paradigm to establish whether the antibodies currently available for measuring digoxin would measure digoxin metabolites in a manner proportional to their reported biological activity. We compared the immunoassay results with various bioassay responses to the major metabolites of digoxin.
We found the TDx, Stratus, Magic, and RIA assays to be relatively insensitive to the removal of terminal digitoxose residues from digoxin, with cross-reactivities near or >100%. The antibody used in the ACS assay, however, was sensitive to the presence and number of digitoxose sugars, with cross-reactivities decreasing as the sugars are sequentially removed. None of the assays had significant cross-reactivity with DHD. The greatest difference between the ACS assay and the other assays was in the cross-reactivity with digoxigenin (0.7% in the ACS assay and 103-153% in the other assays). Metabolite cross-reactivities for the ACS (25, 26) , TDx (26, 27), and Stratus (26) assays have been reported to be higher than our results ( Table 1 The closest model in humans seems to be the human heart ouabain-receptor work by Bednarczyk et al. (9) . Consequently, we compared the immunoassay cross-reactivity results with the radioreceptor studies of the human heart tissue system. We tested digoxin metabolites individually and also in proportional mixtures [as would be seen in human serum in treated patients In experiments with individual digoxin metabolites added to serum, our data (Fig. 2) 1.27) . Numbersreferto the indMdual samples listed In Table 3 . Table 3 . Apparent digoxin in mixtures of metabolites.
the ACS assay and the response of the digoxin metabolites in the human heart ouabain-receptor displacement assay (9) . In the ACS assay DB is slightly above and DG is slightly below the line of identity (Fig. 2) relating immunoactivity with ouabain receptor activity. For the other assays the immunoactivities of DB, DM, and DG are much greater than the receptor activity of these metabolites.
In other experiments the proportions of digoxin metabolites were varied to simulate proportions that might be present in a patient; these results also indicate that the ACS immunoassay responds like the receptor-based assay ( Fig. 3; slope, 1.03 ; y-intercept, 0.03; r, 0.862). The other assays showed significantly higher measured apparent digoxin and poorer correlations with the human heart tissue radioreceptor assay (Fig. 3) of polar metabolites in patients' sera varied between 25% and 85% (mean 33%). Given this degree of cross-reactivity and the probability that these metabolites are relatively inactive, polar metabolites may contribute substantially to discrepancies between the immunoactivity and pharmacological activity in serum samples.
In conclusion, we have found that one digoxin immunoassay (ACS) closely approximates the response of a human heart receptor-based assay when DB, DM, and DG are present, whereas other immunoassays (TDx, Stratus, and Magic) do not. This approach provides a "bioactive average" response that may set the standard for future digoxin immunoassays.
This latter premise needs to be studied in patients undergoing digoxin therapy under a variety of controlled conditions. Our findings with the digoxin model are important because they demonstrate that the concept of developing antibodies that mimic the ligand response to natural receptors is apparently achievable. Extension of this principle to other drugs with active metabolites may represent a marked improvement in TDM over current immunoassays for measuring drugs in serum.
